Clene Nanomedicine, Inc
6550 S. Millrock Dr.
Suite G50
Salt Lake City
UT
84121
United States
32 articles with Clene Nanomedicine, Inc
-
Clene, Inc. released data that shows its add-on treatment, CNM-Au8, significantly improved survival in patients with amyotrophic lateral sclerosis (ALS) by 70%.
-
With one in three employed women in the U.S. also raising children at home, and the majority of U.S. moms working at least part-time, moms are working overtime to keep up with their male counterparts.
-
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
6/27/2022
Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that Rob Etherington, the Company’s President and CEO, has been invited to participate in the “Innovations in ALS - Exploring New Treatments In Development” virtual panel presented by Maxim Group.
-
If you’re considering a career change from pharma to biotech, you’ll be happy to hear that according to industry experts, the transition is more common than you might think.
-
BioSpace spoke with industry experts to find out the differences between working in pharma and biotech and how to know if a pharma company is right for you.
-
A post hoc analysis of data from the Phase II CENTAUR study showed a 10.6-month longer median survival duration for AMX0035 participants, Amylyx announced Thursday.
-
A meeting with an amyotrophic lateral sclerosis (ALS) patient in Israel who could only speak with the assistance of a computer changed the life and direction of NeuroSense CEO Alon Ben-Noon.
-
Data from Clene's RESCUE-ALS trial showed that treatment with CNM-Au8 significantly slowed progression of ALS and improved quality of life.
-
Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe
12/15/2021
Clene Inc. announced it has validated key patents granted by the European Patent Office that protect the Company’s breakthrough processes, devices and methods for treating certain disease indications for its nanotherapeutic drugs.
-
Clene Nanomedicine’s Facility Improvement Project Receives $1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD)
12/13/2021
Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc. announced a $1 million grant award from the Maryland Department of Housing and Community Development to further support the redevelopment of the Clene manufacturing facility in Elkton, MD.
-
Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND
12/10/2021
Clene Inc. presented data from the RESCUE-ALS Phase 2 study of CNM-Au8®, a catalytically active gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis (ALS) in a late-breaking oral presentation at the 32nd International Symposium on ALS/MND, Dec. 10, 2021 at 1:05 pm ET.
-
Clene Nanomedicine’s RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MND
12/7/2021
Clene Inc. announced the 32nd International Symposium on ALS/MND, a Motor Neurone Disease (MND) Association event, has selected Clene’s Phase 2 RESCUE-ALS clinical trial results of CNM-Au8®, a gold nanocrystal suspension, in the treatment of amyotrophic lateral sclerosis (ALS) for a late-breaking oral presentation as well as a poster presentation.
-
An announcement lit up the global grapevine today as Clene Nanomedicine released the results from Phase II of their RESCUE-ALS clinical trial.
-
Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial
11/2/2021
Clene Inc. today announced top-line data from RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS).
-
QurAlis' first piece of the puzzle is a protein called stathmin-2, which is encoded by the STMN2 gene.
-
Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis
9/23/2021
Clene Inc. announced the launch of a second U.S. Food and Drug Administration expanded access program with CNM-Au8 for people living with amyotrophic lateral sclerosis.
-
Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021
9/17/2021
Clene Inc. announced a poster presentation titled “Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8” at the International Parkinson and Movement Disorder Society Virtual Congress 2021 which takes place September 17 – 22, 2021.
-
Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences - Aug 31, 2021
8/31/2021
Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, announced that the Company will present at the following investor conferences in September:.
-
Clene Enters into Two Leases to Materially Expand Manufacturing Capacity of its Lead Asset CNM-Au8®
8/11/2021
Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, announced the completion of two lease agreements that will more than quadruple the company’s manufacturing capacity for its lead asset, CNM-Au8®, a gold nanocrystal suspension.
-
Clinical Catch-Up: August 2-6
8/9/2021
It was a busy week for clinical trial announcements. Take a look.